Trial reportmBio2023
Early antibody treatment, inflammation, and risk of post-COVID conditions.
Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph
Trial report in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Convalescent plasma for people with COVID-19.The Cochrane database of systematic reviews · 2026Pooled it
- COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.Microbiology spectrum · 2024Trial
- Peripheral blood cytokines during early and post-acute stages of SARS-CoV-2 infection are associated with disease severity and long-term symptoms.Frontiers in immunology · 2026Article
- Association of COVID vaccinations and treatments with long COVID beyond 6 months: a case-control study on the adult population in a large integrated healthcare system in the United States from 2020 to 2023.Preventive medicine reports · 2025Article
- Development and internal validation of a prediction model for post-COVID-19 condition 2 years after infection-results of the CORFU study.Diagnostic and prognostic research · 2025Article
- Stable SARS-CoV-2 antibody levels and functionality in serum and COVID-19 convalescent plasma after long-term storage.Vox sanguinis · 2025Article
- Long COVID: A Systematic Review of Preventive Strategies.Infectious disease reports · 2025Review
- Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival.mBio · 2025Article
- Distinct proteomic signatures in Ethiopians predict acute and long-term sequelae of COVID-19.Frontiers in immunology · 2025Article
- Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.Open forum infectious diseases · 2024Review
- Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.EClinicalMedicine · 2024Article
- Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition.International journal of molecular sciences · 2024Review
- Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- COVID-19 Convalescent Plasma Therapy: Long-term Implications.Open forum infectious diseases · 2024Article
- Unveiling the occurrence of COVID-19 in a diverse Bangladeshi population during the pandemic.Frontiers in public health · 2024Article
- Hydrogen Sulfide Ameliorates SARS-CoV-2-Associated Lung Endothelial Barrier Disruption.Biomedicines · 2023Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
44 authors at 18 institutions in 1 country.
Kelly A GeboDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Sonya L HeathDepartment of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama, USA.
Yuriko FukutaDepartment of Medicine, Section of Infectious Diseases, Baylor College of Medicine , Houston, Texas, USA.
Xianming ZhuDepartment of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.ORCID 0000-0002-3317-7449
Sheriza BakshDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Allison G AbrahamDepartment of Epidemiology, University of Colorado, Anschutz Medical Campus , Aurora, Colorado, USA.
Feben HabtehyimerDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
David ShadeDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Jessica RuffDepartment of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Malathi RamDepartement of International Health, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Oliver LaeyendeckerDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH , Baltimore, Maryland, USA.ORCID 0000-0002-6429-4760
Reinaldo E FernandezDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Eshan U PatelDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.ORCID 0000-0003-2174-5004
Owen R BakerDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Shmuel ShohamDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Edward R CachayDepartment of Medicine, Division of Infectious Diseases, University of California , San Diego, California, USA.
Judith S CurrierDepartment of Medicine, Division of Infectious Diseases, University of California , Los Angeles, California, USA.
Jonathan M GerberDepartment of Medicine, Division of Hematology and Oncology, University of Massachusetts Chan Medical School , Worchester, Massachusetts, USA.
Barry MeisenbergLuminis Health , Annapolis, Maryland, USA.
Donald N ForthalDepartment of Medicine, Division of Infectious Diseases, University of California , Irvine, California, USA.ORCID 0000-0001-6687-6775
Laura L HammittDepartement of International Health, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Moises A HuamanDepartment of Medicine, Division of Infectious Diseases, University of Cincinnati , Cincinnati, Ohio, USA.
Adam LevineDepartment of Emergency Medicine, Rhode Island Hospital Warren Alpert Medical School of Brown University , Providence, Rhode Island, USA.
Giselle S MosnaimDepartment of Medicine, Division of Allergy and Immunology, Northshore University Health System , Evanston, Illinois, USA.
Bela PatelDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center , Houston, Texas, USA.
James H PaxtonDepartment of Emergency Medicine, Wayne State University , Detroit, Michigan, USA.
Jay S RavalDepartment of Pathology, University of New Mexico , Albuquerque, New Mexico, USA.
Catherine G SutcliffeDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.ORCID 0000-0001-8512-8326
Shweta AnjanDepartment of Medicine, Division of Infectious Diseases, University of Miami, Miller School of Medicine , Miami, Florida, USA.
Thomas GniadekDepartment of Pathology, Northshore University Health System , Evanston, Illinois, USA.
Seble KassayeDivision of Infectious Diseases, Medstar Georgetown University Hospital , Washington, DC, USA.
Janis E BlairDepartment of Medicine, Division of Infectious Diseases, Mayo Clinic Hospital , Phoenix, Arizona, USA.
Karen LaneDepartment of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Nichol A McBeeDepartment of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Amy L GawadDepartment of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Piyali DasDepartment of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Sabra L KleinDepartment of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.ORCID 0000-0002-0730-5224
Andrew PekoszDepartment of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.ORCID 0000-0003-3248-1761
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.ORCID 0000-0001-8181-9517
Daniel HanleyDepartment of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.ORCID 0000-0002-9402-9167
Aaron A R Tobian *Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.ORCID 0000-0002-0517-3766
David J Sullivan *Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.ORCID 0000-0003-0319-0578
CSSC-004 Consortium
Johns Hopkins University · USNorthShore University HealthSystem · USBaylor College of Medicine · USBrown University · USGeorgetown University · USMayo Clinic Hospital · USNational Institute of Allergy and Infectious Diseases · USThe University of Texas Health Science Center at Houston · USUniversity of Alabama at Birmingham · USUniversity of California, Irvine · USUniversity of California, Los Angeles · USUniversity of California San Diego · USUniversity of Cincinnati · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Massachusetts Chan Medical School · USUniversity of Miami · USUniversity of New Mexico · USWayne State University · US
Funding
Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8MJohns Hopkins-Tufts Trial Innovation Center HEAL Pain ERN SupplementU24TR001609 · NCATS · JOHNS HOPKINS UNIVERSITY · PI HANLEY, DANIEL F · 2016 to 2022
$36.3MConjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1MUnlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3MT-cell depletion and maintenance of the HIV-1 latent reservoir in distinct tissue compartmentsR01DK131926 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Melissa Laird Smith, AARON A TOBIAN · 2022 to 2026
$3.6MColliding Epidemics During an Opioid Crisis: Impact of the COVID-19 Pandemic on Determinants of HIV and HCV Transmission Among People Who Inject DrugsF31DA054849 · NIDA · JOHNS HOPKINS UNIVERSITY · PI PATEL, ESHAN UDAY · 2021 to 2023
$140kNCATS NIH HHS U24 TR001609NCATS NIH HHS UL1 TR001409NIAID NIH HHS R01 AI120938NIAID NIH HHS R01 AI152078NIDA NIH HHS F31 DA054849NIDDK NIH HHS R01 DK131926
Abstract
importanceApproximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.
Indexed as
COVID-19Post-Acute COVID-19 SyndromeAntibodiesCOVID-19 SerotherapyHumansInflammationSARS-CoV-2AntibodieschemokinesCOVID-19COVID-19 serotherapycytokinesinterleukin-6post-acute sequelae of COVID (PASC)post-COVID condition (PCC)
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.